Tarsus (TARS) COO receives new stock option and RSU equity grants

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. reported that Chief Operating Officer Neervannan Seshadri received new equity awards. On March 5, 2026, he was granted stock options for 27,310 shares at an exercise price of $0.00 per share, vesting 25% on March 5, 2027, with the remaining shares vesting monthly over three years, subject to continued service. He also received 17,161 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, contingent on his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Neervannan Seshadri

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	27,310	$0.00	--
Grant/Award	Restricted Stock Units	17,161	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 27,310 shares (Direct); Restricted Stock Units — 17,161 shares (Direct)

Footnotes (1)

1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neervannan Seshadri

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$74.9	03/05/2026		A		27,310		(1)	03/04/2036	Common Stock	27,310	$0	27,310	D
Restricted Stock Units	(2)	03/05/2026		A		17,161		(3)	(3)	Common Stock	17,161	$0	17,161	D

Explanation of Responses:

1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Tarsus Pharmaceuticals (TARS) report for Neervannan Seshadri?

Tarsus Pharmaceuticals reported that COO Neervannan Seshadri received grants of stock options and Restricted Stock Units. The awards increase his potential equity stake over time, aligning part of his compensation with the company’s future stock performance and service-based vesting conditions.

How many stock options were granted to the Tarsus (TARS) COO in this Form 4?

The COO received stock options for 27,310 shares at an exercise price of $0.00 per share. These options vest gradually over four years, starting with a 25% cliff on March 5, 2027, followed by monthly vesting for the remaining shares, contingent on continued service.

What are the vesting terms of the Tarsus (TARS) stock options granted to Neervannan Seshadri?

Twenty-five percent of the option shares vest on March 5, 2027. The remaining option shares then vest in equal monthly installments over the following three years, provided Neervannan Seshadri continues his service with Tarsus Pharmaceuticals during the full vesting period.

How many Restricted Stock Units were granted to the Tarsus (TARS) COO?

Neervannan Seshadri received 17,161 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Tarsus Pharmaceuticals common stock, subject to the specified vesting schedule and his continued service with the company during the vesting period.

What is the vesting schedule for the Tarsus (TARS) Restricted Stock Units in this filing?

The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030. Vesting occurs only if Neervannan Seshadri remains in continuous service with Tarsus Pharmaceuticals through each of these annual vesting dates.

Do the Tarsus (TARS) RSUs and options give immediate ownership of common stock?

The RSUs and options do not immediately deliver common stock. Each RSU represents a contingent right to one share, and options must vest and be exercised. Actual share delivery depends on satisfying the time-based vesting conditions tied to continued service at Tarsus Pharmaceuticals.